Aihara Ken-ichi, Azuma Hiroyuki, Akaike Masashi, Ikeda Yasumasa, Sata Masataka, Takamori Nobuyuki, Yagi Shusuke, Iwase Takashi, Sumitomo Yuka, Kawano Hirotaka, Yamada Takashi, Fukuda Toru, Matsumoto Takahiro, Sekine Keisuke, Sato Takashi, Nakamichi Yuko, Yamamoto Yoko, Yoshimura Kimihiro, Watanabe Tomoyuki, Nakamura Takashi, Oomizu Akimasa, Tsukada Minoru, Hayashi Hideki, Sudo Toshiki, Kato Shigeaki, Matsumoto Toshio
Department of Medicine and Bioregulatory Sciences and 21st Century Center of Excellence Program, The University of Tokushima Graduate School of Health Biosciences, Tokushima, Japan.
J Clin Invest. 2007 Jun;117(6):1514-26. doi: 10.1172/JCI27095.
Heparin cofactor II (HCII) specifically inhibits thrombin action at sites of injured arterial wall, and patients with HCII deficiency exhibit advanced atherosclerosis. However, the in vivo effects and the molecular mechanism underlying the action of HCII during vascular remodeling remain elusive. To clarify the role of HCII in vascular remodeling, we generated HCII-deficient mice by gene targeting. In contrast to a previous report, HCII(-/-) mice were embryonically lethal. In HCII(+/-) mice, prominent intimal hyperplasia with increased cellular proliferation was observed after tube cuff and wire vascular injury. The number of protease-activated receptor-1-positive (PAR-1-positive) cells was increased in the thickened vascular wall of HCII(+/-) mice, suggesting enhanced thrombin action in this region. Cuff injury also increased the expression levels of inflammatory cytokines and chemokines in the vascular wall of HCII(+/-) mice. The intimal hyperplasia in HCII(+/-) mice with vascular injury was abrogated by human HCII supplementation. Furthermore, HCII deficiency caused acceleration of aortic plaque formation with increased PAR-1 expression and oxidative stress in apoE-KO mice. These results demonstrate that HCII protects against thrombin-induced remodeling of an injured vascular wall by inhibiting thrombin action and suggest that HCII is potentially therapeutic against atherosclerosis without causing coagulatory disturbance.
肝素辅因子II(HCII)特异性抑制受损动脉壁部位的凝血酶作用,HCII缺乏的患者表现出晚期动脉粥样硬化。然而,HCII在血管重塑过程中的体内作用及其作用的分子机制仍不清楚。为了阐明HCII在血管重塑中的作用,我们通过基因靶向技术生成了HCII缺陷小鼠。与之前的报道相反,HCII(-/-)小鼠胚胎致死。在HCII(+/-)小鼠中,在套管和钢丝血管损伤后观察到明显的内膜增生,细胞增殖增加。在HCII(+/-)小鼠增厚的血管壁中,蛋白酶激活受体-1阳性(PAR-1阳性)细胞数量增加,表明该区域凝血酶作用增强。套管损伤还增加了HCII(+/-)小鼠血管壁中炎性细胞因子和趋化因子的表达水平。补充人HCII可消除血管损伤的HCII(+/-)小鼠的内膜增生。此外,HCII缺乏导致载脂蛋白E基因敲除(apoE-KO)小鼠主动脉斑块形成加速,PAR-1表达增加和氧化应激。这些结果表明,HCII通过抑制凝血酶作用来保护免受凝血酶诱导的受损血管壁重塑,并表明HCII在不引起凝血紊乱的情况下对动脉粥样硬化具有潜在的治疗作用。